 Timothy Jenkins
Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 35 | 2024 | 1477 | 6.310 |
Why?
| | Antimicrobial Stewardship | 11 | 2024 | 94 | 4.960 |
Why?
| | Skin Diseases, Bacterial | 7 | 2016 | 22 | 2.840 |
Why?
| | Otitis Media | 5 | 2023 | 143 | 2.780 |
Why?
| | Inappropriate Prescribing | 6 | 2021 | 52 | 2.000 |
Why?
| | Drug Utilization | 5 | 2020 | 167 | 1.990 |
Why?
| | Practice Patterns, Physicians' | 10 | 2023 | 1178 | 1.950 |
Why?
| | Soft Tissue Infections | 4 | 2018 | 30 | 1.860 |
Why?
| | Bacteremia | 7 | 2024 | 159 | 1.800 |
Why?
| | Abscess | 4 | 2015 | 72 | 1.400 |
Why?
| | Anti-Infective Agents | 7 | 2020 | 225 | 1.360 |
Why?
| | Ambulatory Care | 6 | 2020 | 479 | 1.340 |
Why?
| | Skin Diseases | 3 | 2015 | 122 | 1.200 |
Why?
| | Hospitalization | 7 | 2017 | 1752 | 1.200 |
Why?
| | Drug Prescriptions | 3 | 2020 | 239 | 1.170 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.140 |
Why?
| | Staphylococcal Infections | 5 | 2023 | 336 | 1.130 |
Why?
| | Conjunctivitis | 2 | 2023 | 17 | 0.990 |
Why?
| | Guideline Adherence | 4 | 2022 | 490 | 0.870 |
Why?
| | Cellulitis | 2 | 2014 | 45 | 0.830 |
Why?
| | Urinary Tract Infections | 3 | 2018 | 133 | 0.770 |
Why?
| | Fluoroquinolones | 3 | 2024 | 41 | 0.770 |
Why?
| | Inpatients | 3 | 2020 | 378 | 0.750 |
Why?
| | Gram-Negative Bacterial Infections | 2 | 2018 | 37 | 0.710 |
Why?
| | Cross Infection | 2 | 2015 | 197 | 0.700 |
Why?
| | Retrospective Studies | 20 | 2024 | 12515 | 0.680 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 155 | 0.640 |
Why?
| | Substance Abuse, Intravenous | 2 | 2020 | 99 | 0.620 |
Why?
| | Pharyngitis | 1 | 2018 | 24 | 0.610 |
Why?
| | Humans | 49 | 2024 | 114756 | 0.590 |
Why?
| | Smartphone | 1 | 2018 | 72 | 0.590 |
Why?
| | Colorado | 9 | 2020 | 4086 | 0.580 |
Why?
| | Infection Control | 2 | 2017 | 135 | 0.570 |
Why?
| | Nitrofurantoin | 1 | 2017 | 7 | 0.560 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 13 | 0.560 |
Why?
| | Cystitis | 1 | 2017 | 20 | 0.560 |
Why?
| | Emergency Service, Hospital | 5 | 2020 | 1812 | 0.550 |
Why?
| | Staphylococcus aureus | 3 | 2023 | 385 | 0.530 |
Why?
| | Mobile Applications | 1 | 2018 | 140 | 0.530 |
Why?
| | Sinusitis | 1 | 2018 | 175 | 0.520 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 25 | 0.490 |
Why?
| | Acute Disease | 4 | 2023 | 912 | 0.490 |
Why?
| | Drug Users | 1 | 2015 | 41 | 0.490 |
Why?
| | Child | 12 | 2024 | 18352 | 0.470 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 39 | 0.460 |
Why?
| | Medication Therapy Management | 1 | 2015 | 67 | 0.460 |
Why?
| | Cohort Studies | 9 | 2024 | 4901 | 0.450 |
Why?
| | Practice Guidelines as Topic | 4 | 2017 | 1393 | 0.440 |
Why?
| | Osteomyelitis | 2 | 2012 | 101 | 0.430 |
Why?
| | Escherichia coli | 1 | 2017 | 722 | 0.430 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2023 | 191 | 0.420 |
Why?
| | Streptococcus pneumoniae | 2 | 2023 | 134 | 0.420 |
Why?
| | Community-Acquired Infections | 5 | 2017 | 141 | 0.420 |
Why?
| | Patient Discharge | 2 | 2017 | 769 | 0.410 |
Why?
| | Critical Pathways | 1 | 2013 | 74 | 0.400 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2012 | 38 | 0.400 |
Why?
| | Drug Utilization Review | 3 | 2016 | 57 | 0.380 |
Why?
| | Histoplasmosis | 1 | 2011 | 14 | 0.380 |
Why?
| | Humeral Head | 1 | 2011 | 13 | 0.380 |
Why?
| | Middle Aged | 15 | 2018 | 26757 | 0.370 |
Why?
| | Fistula | 1 | 2011 | 26 | 0.370 |
Why?
| | Adult | 18 | 2024 | 30548 | 0.370 |
Why?
| | Muscular Diseases | 1 | 2011 | 104 | 0.360 |
Why?
| | Arm | 1 | 2011 | 103 | 0.360 |
Why?
| | Ambulatory Care Facilities | 2 | 2024 | 212 | 0.350 |
Why?
| | Female | 20 | 2021 | 59507 | 0.330 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 319 | 0.330 |
Why?
| | Outpatients | 3 | 2021 | 327 | 0.320 |
Why?
| | Male | 18 | 2024 | 55579 | 0.320 |
Why?
| | Sepsis | 2 | 2024 | 508 | 0.300 |
Why?
| | Hospitals | 3 | 2024 | 580 | 0.290 |
Why?
| | Academic Medical Centers | 3 | 2017 | 413 | 0.270 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 904 | 0.270 |
Why?
| | Prescriptions | 2 | 2018 | 60 | 0.270 |
Why?
| | Drug and Narcotic Control | 2 | 2016 | 29 | 0.260 |
Why?
| | Aged, 80 and over | 5 | 2018 | 6350 | 0.260 |
Why?
| | Health Services Research | 1 | 2008 | 371 | 0.250 |
Why?
| | HIV | 1 | 2006 | 208 | 0.240 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 228 | 0.240 |
Why?
| | Child, Preschool | 4 | 2021 | 9079 | 0.230 |
Why?
| | Aged | 7 | 2024 | 19094 | 0.220 |
Why?
| | Daptomycin | 1 | 2023 | 18 | 0.220 |
Why?
| | Pandemics | 2 | 2022 | 1319 | 0.220 |
Why?
| | Program Evaluation | 3 | 2017 | 822 | 0.220 |
Why?
| | Organizational Policy | 2 | 2017 | 68 | 0.210 |
Why?
| | Muscle, Skeletal | 1 | 2011 | 1472 | 0.200 |
Why?
| | Prospective Studies | 3 | 2022 | 6217 | 0.200 |
Why?
| | Treatment Outcome | 6 | 2023 | 9089 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1214 | 0.190 |
Why?
| | Cephalosporins | 2 | 2023 | 26 | 0.190 |
Why?
| | Risk Factors | 5 | 2014 | 8627 | 0.190 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 19 | 0.190 |
Why?
| | Logistic Models | 2 | 2018 | 1843 | 0.190 |
Why?
| | Bacterial Infections | 2 | 2020 | 219 | 0.190 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 718 | 0.180 |
Why?
| | Electronic Health Records | 2 | 2024 | 801 | 0.180 |
Why?
| | Health Services Accessibility | 1 | 2006 | 763 | 0.170 |
Why?
| | Private Sector | 1 | 2020 | 51 | 0.170 |
Why?
| | Mass Screening | 1 | 2006 | 1003 | 0.160 |
Why?
| | Drug Combinations | 2 | 2024 | 286 | 0.160 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 56 | 0.150 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 4409 | 0.150 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 102 | 0.150 |
Why?
| | Insurance, Health | 1 | 2020 | 244 | 0.150 |
Why?
| | Pneumonia, Bacterial | 2 | 2017 | 106 | 0.150 |
Why?
| | Drug Costs | 1 | 2017 | 91 | 0.140 |
Why?
| | Medical Audit | 1 | 2017 | 75 | 0.140 |
Why?
| | Medical Records | 1 | 2017 | 153 | 0.130 |
Why?
| | Linear Models | 1 | 2018 | 770 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 176 | 0.130 |
Why?
| | Time | 1 | 2015 | 70 | 0.120 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 67 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 332 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 235 | 0.120 |
Why?
| | Debridement | 2 | 2012 | 73 | 0.120 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.120 |
Why?
| | Wound Infection | 1 | 2014 | 30 | 0.120 |
Why?
| | Infant | 3 | 2023 | 7935 | 0.120 |
Why?
| | Safety Management | 1 | 2015 | 109 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 951 | 0.110 |
Why?
| | Adolescent | 3 | 2018 | 17808 | 0.110 |
Why?
| | Urinalysis | 1 | 2013 | 63 | 0.110 |
Why?
| | Age Factors | 1 | 2020 | 2890 | 0.110 |
Why?
| | Catheter-Related Infections | 1 | 2013 | 61 | 0.100 |
Why?
| | Diabetic Foot | 1 | 2012 | 22 | 0.100 |
Why?
| | Databases, Factual | 1 | 2017 | 1128 | 0.100 |
Why?
| | Limb Salvage | 1 | 2012 | 52 | 0.100 |
Why?
| | HIV Infections | 1 | 2006 | 2469 | 0.100 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2012 | 79 | 0.100 |
Why?
| | Hospitals, Urban | 1 | 2012 | 127 | 0.100 |
Why?
| | Histoplasma | 1 | 2011 | 12 | 0.100 |
Why?
| | Algorithms | 1 | 2018 | 1468 | 0.100 |
Why?
| | Bacteria | 2 | 2023 | 726 | 0.090 |
Why?
| | Streptomycin | 1 | 2011 | 13 | 0.090 |
Why?
| | Penicillin G | 1 | 2011 | 7 | 0.090 |
Why?
| | Young Adult | 2 | 2018 | 10463 | 0.090 |
Why?
| | Enterococcus faecalis | 1 | 2011 | 23 | 0.090 |
Why?
| | Blood | 1 | 2010 | 96 | 0.090 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2011 | 61 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2013 | 351 | 0.080 |
Why?
| | United States | 3 | 2021 | 12176 | 0.080 |
Why?
| | Incidence | 1 | 2015 | 2312 | 0.080 |
Why?
| | Critical Care | 1 | 2013 | 473 | 0.080 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 62 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4625 | 0.080 |
Why?
| | Ultrasonography | 1 | 2011 | 629 | 0.070 |
Why?
| | Endocarditis | 1 | 2008 | 32 | 0.070 |
Why?
| | Recurrence | 1 | 2010 | 936 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2009 | 310 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2011 | 369 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1340 | 0.070 |
Why?
| | Infectious Disease Medicine | 2 | 2016 | 10 | 0.070 |
Why?
| | Epidemiology | 2 | 2016 | 14 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2013 | 723 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 811 | 0.060 |
Why?
| | Echocardiography | 1 | 2008 | 554 | 0.060 |
Why?
| | Ceftazidime | 1 | 2024 | 5 | 0.060 |
Why?
| | Carbapenems | 1 | 2024 | 16 | 0.060 |
Why?
| | Aztreonam | 1 | 2023 | 8 | 0.060 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 44 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2023 | 48 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2008 | 632 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 62 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2023 | 124 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 45 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2024 | 301 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 73 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 385 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3039 | 0.040 |
Why?
| | Health Facilities | 1 | 2020 | 72 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1662 | 0.040 |
Why?
| | Coagulase | 1 | 2018 | 6 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 68 | 0.040 |
Why?
| | Staphylococcus | 1 | 2018 | 69 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2018 | 258 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 309 | 0.040 |
Why?
| | Cost Savings | 1 | 2017 | 74 | 0.040 |
Why?
| | Clinical Studies as Topic | 1 | 2017 | 6 | 0.040 |
Why?
| | Pharmacy Service, Hospital | 1 | 2017 | 83 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 65 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2763 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2020 | 474 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 151 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 479 | 0.030 |
Why?
| | Leadership | 1 | 2017 | 292 | 0.030 |
Why?
| | Fever | 1 | 2013 | 279 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 316 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 372 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1122 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1691 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2012 | 4420 | 0.010 |
Why?
|
|
Jenkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|